OMEICOS Therapeutics is a biopharmaceutical company that has developed a small molecule technology for the prevention and treatment of cardiovascular diseases including atrial fibrillation. Their technology is based on the discovery of natural metabolites of omega-3 fatty acids that activate anti-inflammatory, anti-arrhythmic, and cardioprotective pathways in heart cells, providing curative effects to the diseased organ by preventing its electrical and structural remodeling. The company has discovered a series of metabolically robust synthetic analogues of omega-3 fatty acid derived epoxyeicosanoids that are orally available and show significantly improved biological activity and pharmacokinetic properties compared to their natural counterparts. The first development project makes use of the strong anti-arrhythmic effect of the compounds for the development of an oral therapy for atrial fibrillation that activates an endogenous cardio-protective signalling pathway. OMEICOS was founded as a spin-off from the Max-Delbrück-Center in Berlin, based on ground-breaking scientific results in the field of omega-3 fatty acid metabolism and physiology obtained by the companies’ founders.